Evolocumab in STEMI

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2020

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
Epistemonikos ID: b6665b9fd425500fda3bcd6f093d1d424d77aece
First added on: May 15, 2024